Materiały źródłowe

• #1 Rare brain embryonal tumors in infancy and early childhood | MedLink Neurology

  https://www.medlink.com/articles/rare-brain-embryonal-tumors-in-infancy-and-early-childhood

  Embryonal brain tumors account for approximately 13% of primary brain tumors of childhood, following gliomas as the second most common CNS tumor type in children up to 14 years of age. […] Brain tumors may be congenital in children younger than 3 years of age and range from benign complex lesions to highly malignant neoplasms. They differ from those in older children with regard to histology, presentation symptoms, and treatment options, with historically lower survival outcomes. […] Approximately 10% to 15% of all childhood brain tumors will appear in the first 2 years of life, and about half occur in the first 6 months; overall, they are considered rare. Embryonal tumors represent 25% of brain tumors in infants younger than 1 year of age. […] Many rare embryonal tumors are believed to be congenital, and they present during times of maximum brain growth and development. They occur when the child’s skull is able to expand, resulting in the development of macrocephaly and often masking the signs and symptoms of increased intracranial pressure.

• #2

  https://braintumourresearch.org/pages/types-of-brain-tumours-embryonal-tumours?srsltid=AfmBOopgWZYlC6zgqhNs-WM9neO1MlS4Yc5_hIdBfbEiKQOQPNfbxMEq

  Embryonal tumours represent 20% to 25% of primary paediatric central nervous system (CNS) tumours, with medulloblastoma accounting for the majority of these tumours. […] The prognosis for each type of embryonal tumour is included in the relevant section above, but overall survival rates for embryonal tumours (not including medulloblastoma) are generally poor, ranging from less than 5% to 50% of patients surviving more than 5 years from diagnosis. […] Signs and symptoms of embryonal tumours depend upon where the tumour has developed. Common symptoms include headaches, seizures, muscular weakness or partial paralysis of facial muscles, and muscular weakness or partial paralysis on one side of the body.

• #3 Embryonal tumours | Brain and spinal cord tumours | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/embryonal-tumours

  Embryonal tumours can start anywhere in the brain or the spinal cord. They are likely to grow quickly and can spread through the cerebrospinal fluid to other parts of the brain and the spinal cord (high grade tumour). […] Common symptoms of brain tumours include headaches, feeling or being sick and seizures (fits).

• #4 Rare brain embryonal tumors in infancy and early childhood | MedLink Neurology

  https://www.medlink.com/articles/rare-brain-embryonal-tumors-in-infancy-and-early-childhood

  The clinical presentation is based on the location of the tumor and encompasses symptoms of raised intracranial pressure (eg, headache, vomiting, nausea, visual disturbances), focal neurologic deficits, ataxia, and seizures. […] The limited case series available describe very poor prognosis with a median survival of 21 months (5-year overall survival less than 60%, 10-year overall survival less than 30%) and a propensity for early disease progression or recurrence.

• #5 Embryonal tumors – Augusta HealthSearchClose SearchSearch IconSearch IconClose Search IconMobile Menu IconMobile Menu Close IconInstagramFacebookTwitterYoutube

  https://www.augustahealth.com/disease/embryonal-tumors/

  Signs and symptoms of embryonal tumors vary, depending on the type of tumor, location, severity and other factors, such as pressure buildup within the brain. Symptoms may include, for example, headaches, nausea, vomiting, unusual tiredness, dizziness, double vision, unsteady walk, seizures or other issues. […] Embryonal tumors can occur at any age, but most often occur in babies and young children.

• #6 Mayo Clinic Health Library – Embryonal tumors | Swiss Medical Network

  https://www.swissmedical.net/en/healtcare-library/con-20367936

  Symptoms of an embryonal tumor may include: Headaches. Nausea. Vomiting. Feeling more tired than usual. Double vision. Difficulty with balance. Seizures. […] Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you. […] Treatment for embryonal tumors usually involves surgery. Other treatments might be used after surgery to reduce the risk that the tumor may come back. Which treatments are best for your child depends on your child’s age. Your child’s healthcare team also considers the type of embryonal tumor and its location.

• #7 Embryonal tumor with multilayered rosettes | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/embryonal-tumour-with-multilayered-rosettes?lang=us

  Embryonal tumors with multilayered rosettes (ETMR) are rare small round blue cell tumor of the central nervous system. They are one of the most aggressive brain tumors usually encountered in children and are WHO grade 4 tumors. […] The clinical features are determined by the location and extent of the tumor. Most are supratentorial in location, a few are infratentorial, and they are very rarely encountered in the spinal cord. […] Increased intracranial pressure, seizures, hemiparesis, cerebellar signs, cranial nerve palsies, and other neurologic deficits have all been reported. […] Unfortunately, the prognosis is dismal, with articles reporting ~75% of cases have died within the median survival of 9 months.

• #8 Embryonal tumors – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/embryonal-tumor/symptoms-causes/syc-20579617

  Embryonal tumors are growths of cells that happen in the brain. The growths involve cells that are left over from fetal development, called embryonal cells. […] Symptoms of an embryonal tumor may include: Headaches. Nausea. Vomiting. Feeling more tired than usual. Double vision. Difficulty with balance. Seizures. […] Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you.

• #9 Embryonal tumors | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/embryonal-tumors

  Symptoms of an embryonal tumor may include: […] Headaches. […] Nausea. […] Vomiting. […] Feeling more tired than usual. […] Double vision. […] Difficulty with balance. […] Seizures.

• #10 Embryonal tumors | Beacon Health System

  https://www.beaconhealthsystem.org/library/diseases-and-conditions/embryonal-tumors?content_id=CON-20367936

  Symptoms of an embryonal tumor may include: Headaches. Nausea. Vomiting. Feeling more tired than usual. Double vision. Difficulty with balance. Seizures. […] Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you.

• #11

  https://www.nicklauschildrens.org/conditions/embryonal-brain-tumors

  Symptoms vary depending on the site, size, location and speed of growth of the tumor and may include: […] headaches […] unexplained nausea and vomiting […] vision problems […] seizures […] weakness and difficulty walking […] memory loss […] confusion […] personality changes […] balance problems […] speech issues […] irritability […] and other symptoms. […] The tumors can grow and press on other parts of the brain, growing quickly and spreading through the fluid surrounding the brain and spinal cord (cerebrospinal fluid-CSF) to other parts of the brain and spinal cord.

• #12

  https://www.meetaugust.ai/en/library/diseases-conditions/view/embryonal-tumor

  Symptoms of an embryonal tumor can include: Headaches, Nausea, Vomiting, Extreme tiredness, Dizziness, Double vision, Trouble walking, Seizures, Other potential problems […] If your child is suspected to have an embryonal tumor, it’s crucial to seek care at a medical center experienced in treating pediatric brain tumors. […] It’s important to discuss all treatment options with your child’s healthcare team to determine the best course of action based on the specific type and location of the tumor, as well as your child’s age and overall health.

• #13 Primitive Neuroectodermal Tumor – MD Searchlight

  https://mdsearchlight.com/cancer/primitive-neuroectodermal-tumor/

  Embryonal tumors are a type of brain cancer often identified by increasing pressure in the brain. The common symptoms typically include headache, nausea, vomiting, irritability, and lethargy. Patients may also have visual issues, seizures, or experience weakness on one side of the body. Certain symptoms such as problems with coordination, balance, or other nervous system functions may also be apparent. It’s important to note that symptoms can depend on where the tumor is located in the brain, how old the patient is, and whether the tumor is of a high grade. […] For instance, a tumor in the lower part (infratentorial) of the brain often leads to increased brain fluid, causing symptoms like headache, vomiting, irritability, and lethargy. There might also be issues with balance and muscle coordination, and problems related to the functioning of cranial nerves, which affect areas of the body like the face, eyes, tongue, and throat. Seizures are rare with these tumors. On the other hand, tumors in the upper (supratentorial) region of the brain commonly cause vomiting, seizures, and headaches. If they impact the motor areas, the patient may experience hemiparesis, or weakness on one side of the body.

• #14 Childhood Medulloblastoma & Other CNS Embryonal Tumors Treatment – NCI

  https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq

  Medulloblastoma and other central nervous system (CNS) embryonal tumors may begin in embryonic (fetal) cells that remain in the brain after birth. […] Symptoms of medulloblastoma, other CNS embryonal tumors, and pineoblastoma depend on the child’s age and where the tumor is. […] Children may not have symptoms of medulloblastoma, other CNS embryonal tumors, or pineoblastoma until the tumor has grown bigger. It’s important to check with your child’s doctor if your child has: loss of balance, trouble walking, lack of coordination, or slow speech; a headache, especially in the morning, or headache that goes away after vomiting; general weakness; weakness on one side of the face; unusual sleepiness or change in energy level; seizures; double vision or other eye problems; nausea and vomiting.

• #15 Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment – Health Professional Information [NCI] – Health Information Library | PeaceHealth

  https://www.peacehealth.org/medical-topics/id/ncicdr0000548358

  The optimal treatment of childhood nonmedulloblastoma embryonal tumors remains unclear and under study. […] Nonmedulloblastoma embryonal tumors may occur anywhere in the CNS, and presentation is variable. Usually there is significant neurological dysfunction associated with lethargy and vomiting. […] For nonmedulloblastoma embryonal tumors, presentation is also relatively rapid and depends on the location of the tumor in the nervous system. Embryonal tumors tend to grow fast and are usually diagnosed within 3 months of initial onset of symptoms. […] In one study of 58 children with pineoblastoma, a subclassification schema was presented, and it separated patients into four subgroups. […] Pineoblastoma often results in hydrocephalus due to blockage of cerebrospinal fluid at the third ventricular level and other symptoms related to pressure on the back of the brain stem in the tectal region. Symptoms may include a constellation of abnormalities in eye movements (Parinaud syndrome), manifested by pupils that react poorly to light but better to accommodation, loss of upgaze, retraction or convergence nystagmus, and lid retraction.

• #16

  https://journals.lww.com/ijno/fulltext/2021/04001/diagnosis_and_management_of_central_nervous_system.28.aspx

  Central nervous system (CNS) embryonal tumors exhibit significant biological heterogeneity and pose challenges in diagnosis and clinical management. […] Patients with medulloblastoma generally present acutely or subacutely with features of raised intracranial pressure such as headache, nausea, vomiting, blurring of vision, and cranial nerve deficits or signs and symptoms of cerebellar/brainstem involvement in the form of ataxia, dysarthria, dysmetria, and gaze palsy. […] Since a significant proportion of infants and toddlers are also affected with embryonal CNS tumors, diagnosis can sometimes be challenging with generalized symptoms such as increasing irritability, lethargy, poor feeding, vomiting, developmental delay, and failure to thrive. […] Maximal safe resection of the tumor via microneurosurgical approach is the recommended first-line treatment in the multimodality management of medulloblastoma and other embryonal CNS tumors.

• #17 Childhood Medulloblastoma & Other CNS Embryonal Tumors Treatment – NCI

  https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq

  Infants and young children with these tumors may be irritable or grow slowly. Also they may not eat well or meet developmental milestones such as sitting, walking, and talking in sentences. These tumors may also cause an increase in the size of an infant’s head. […] These symptoms may be caused by problems other than medulloblastoma, other CNS embryonal tumors, or pineoblastoma. The only way to know is to see your child’s doctor. […] Most medulloblastomas, other CNS embryonal tumors, and pineoblastomas in children are malignant. These tumors tend to spread through the cerebrospinal fluid to other parts of the brain and spinal cord. […] Childhood medulloblastoma is caused by certain changes to the way brain cells function, especially how they grow and divide into new cells. Often, the exact cause of the cell changes is unknown.

• #18 Embryonal Tumor with Multilayered Rosettes (ETMR) | Nationwide Children’s Hospital

  https://www.nationwidechildrens.org/conditions/embryonal-tumor-with-multilayered-rosettes

  Symptoms of brain tumors depend on where they are in the brain, how big they are and the child’s age (under age 3). When the tumors press on important parts of the brain, they may cause problems such as: […] These problems can be difficult to notice in young children who cannot describe them. It may also be hard to know if your child is having trouble with balance or language if your child is barely walking or talking yet. […] If you are worried about your childs symptoms or development, reach out to a physician. The sooner your child is diagnosed, the better the chances are of survival.

• #19

  https://www.cancerhelpessentiahealth.org/Cancer_Types/child_cns_embryonal_277378E1_01.html

  Signs and symptoms of childhood CNS embryonal tumors or pineoblastomas depend on the child’s age and where the tumor is. […] These and other signs and symptoms may be caused by childhood CNS embryonal tumors, pineoblastomas, or other conditions. Check with your child’s doctor if your child has any of the following: Loss of balance, trouble walking, worsening handwriting, or slow speech. Lack of coordination. Headache, especially in the morning, or headache that goes away after vomiting. Double vision or other eye problems. Nausea and vomiting. General weakness or weakness on one side of the face. Unusual sleepiness or change in energy level. Seizures. […] Infants and young children with these tumors may be irritable or grow slowly. Also they may not eat well or meet developmental milestones such as sitting, walking, and talking in sentences.

• #20 Rare brain embryonal tumors in infancy and early childhood | MedLink Neurology

  https://www.medlink.com/articles/rare-brain-embryonal-tumors-in-infancy-and-early-childhood

  Embryonal brain tumors account for approximately 13% of primary brain tumors of childhood, following gliomas as the second most common CNS tumor type in children up to 14 years of age. […] Brain tumors may be congenital in children younger than 3 years of age and range from benign complex lesions to highly malignant neoplasms. They differ from those in older children with regard to histology, presentation symptoms, and treatment options, with historically lower survival outcomes. […] Approximately 10% to 15% of all childhood brain tumors will appear in the first 2 years of life, and about half occur in the first 6 months; overall, they are considered rare. Embryonal tumors represent 25% of brain tumors in infants younger than 1 year of age. […] Many rare embryonal tumors are believed to be congenital, and they present during times of maximum brain growth and development. They occur when the child’s skull is able to expand, resulting in the development of macrocephaly and often masking the signs and symptoms of increased intracranial pressure.

• #21 What are the symptoms of Central Nervous Embyryonal Tumour? | OnlyMyHealth

  https://www.onlymyhealth.com/what-symptoms-central-nervous-embyryonal-tumour-12977607046

  The symptoms of childhood CNS embryonal tumors are not the same in every child. The following symptoms and others may be caused by a CNS embryonal tumor. Symptoms vary depending on the child’s age and where the tumor is located. Other conditions may cause the same symptoms. A doctor should be consulted if any of the following problems occur: Loss of balance, trouble walking, worsening handwriting, or slow speech. Morning headache or headache that goes away after vomiting. Nausea and vomiting. General weakness or weakness on one side of the face. Unusual sleepiness or change in energy level. Change in personality or behavior. Unexplained weight loss or weight gain. […] An infant or young child may be irritable or grow slowly, and may not eat well or meet developmental milestones such as sitting, walking, and talking in sentences.

• #22 Rare brain embryonal tumors in infancy and early childhood | MedLink Neurology

  https://www.medlink.com/articles/rare-brain-embryonal-tumors-in-infancy-and-early-childhood

  The signs and symptoms of brain tumors in children younger than 2 years of age, especially those younger than 1 year, differ significantly from manifestations seen in older patients. […] Non-medulloblastoma embryonal tumors can arise along the CNS with a predominance for the supratentorial compartment; this applies especially to CNS neuroblastoma, FOXR2-activated, which has only been reported in supratentorial locations. […] Embryonal tumors of the pineal region usually cause symptoms of mass effect, including headaches, aqueductal stenosis, and hydrocephalus. […] Children younger than 2 years of age with posterior fossa tumors usually present with vomiting. […] A proportion of children (23%) under the age of 3 years have tumor-related seizures at presentation. […] Due to their embryonal nature, this subset of tumors has a high cellular turnover and a rapid-growing pattern, with some patients presenting with worsening symptoms due to tumor progression even during the course of therapy.

• #23 Embryonal Tumors Causes and Symptoms – Klarity Health Library

  https://my.klarity.health/embryonal-tumors-causes-and-symptoms/

  As the tumor spreads to the spinal cord, it can cause: Backaches, Problems with walking, Bladder and bowel issues. […] Common symptoms associated with AT/RT include: Frequent headaches, Nausea and vomiting, Fatigue, Coordination issues. […] This type of tumor is usually found in the cerebral hemisphere of the brain. ETMR is a malignant type of tumor with low survival rates of only around a year. Some of the symptoms associated with this type of tumor include headaches, seizures and facial paralysis. […] The symptoms include: Fatigue, tiredness, Loss of appetite, Bone pain, Weakness. […] Symptoms of these tumor types are often shared with each other and with other diseases, making it difficult to diagnose. Symptoms also depend on where in the central nervous system the tumor begins to grow. As many of these tumors progress very quickly and are quite debilitating, early detection is vital to ensure best prognosis and survival.

• #24 Medulloblastoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1181219-overview

  Symptoms are often progressive over weeks to months, and it is not uncommon for patients to have an extended symptomatic period prior to initial diagnosis. […] Symptoms usually differ by anatomic location of the tumor, presence of disseminated disease, and by the presence of hydrocephalus. […] Medulloblastoma is a very aggressive tumor. Even after a good response to surgery and radiation, recurrence is common; most recurrences occur within 2 years after treatment. […] The most common location of recurrence is at the primary tumor site in the posterior fossa. […] Systemic metastases, in the absence of a CSF shunting system, are also a recognized problem in 10-20% of patients. Bone is the most common site of systemic metastasis; regional lymph node sites follow. […] The 5-year progression-free survival rate in that group is 70-80% for patients at low risk and 60-70% for patients at high risk.

• #25 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Diagnosis is usually made by either magnetic resonance imaging (MRI) or computed tomography (CT) scan. MRI is preferable because the anatomical relationship between the tumor and surrounding brain and tumor dissemination is better visualized with this method. […] Given the tendency of these tumors to disseminate throughout the CNS early in the course of illness, imaging evaluation of the neuraxis by MRI of the entire brain and spine is indicated. […] Patients with disseminated CNS disease at diagnosis are at highest risk of disease relapse. […] Ten percent to 40% of patients with medulloblastoma have CNS dissemination at diagnosis. Infants have the highest incidence and adolescents and adults have the lowest incidence of CNS dissemination. […] Nonmedulloblastoma embryonal tumors and pineoblastomas may also be disseminated at the time of diagnosis, although the incidence may be somewhat less than for medulloblastomas, with dissemination at diagnosis in approximately 10% to 20% of patients.

• #26 Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience

  https://www.mdpi.com/2227-9067/9/10/1560

  Objective: Embryonal tumors with multilayered rosettes (ETMRs) are highly aggressive pediatric brain tumors with poor prognosis. […] The common clinical presentation was headaches and nausea caused by intracranial hypertension. […] The most common clinical manifestations of ETMRs are nausea, vomiting, and headache caused by increased intracranial pressure. In addition, some children may also show paralysis, epilepsy, visual impairment, ataxia, and torticollis. […] ETMRs primarily occur in children under four years of age; the median onset age is 26–29 months. Many patients die within one year of the diagnosis, and the 5-year overall survival rate is lower than 30%. […] The clinical presentation of ETMRs is similar to other brain tumors, depending on the tumor site and size and the presence or absence of cerebrospinal fluid circulation obstruction.

• #27 ETMR Brain Cancer: Advancing Treatment Protocol – solvingkidscancer.org

  https://solvingkidscancer.org/blog/etmr-brain-cancer-advancing-treatment-protocol/

  Symptoms of an embryonal tumor with multilayered rosettes are different for each patient depending on various factors such as how advanced tumor growth is, location and whether or not the tumor is causing increased intracranial pressure (ICP). […] ETMR symptoms can include: Seizures Headaches Nausea and vomiting Increased lethargy Weakness in the arms and legs Facial weakness and drooping Changes in vision/eye movements (double or blurred vision and uncontrolled movements) Issues with balance, coordination or walking Twisting of the neck (resulting in involuntary head tilting) […] The exact cause of this pediatric cancer is unknown. Still, research shows that Since the discovery of the characteristic chromosome 19 miRNA cluster (C19MC) amplification over a decade ago, the methods for diagnosing this entity have improved and many new insights in the molecular landscape of ETMRs have been acquired.

• #28 Medulloblastoma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 9Group 49

  https://www.barrowneuro.org/condition/medulloblastoma/

  Medulloblastoma Symptoms depend on the tumor’s size, location, and whether it has spread to other parts of the brain or spinal cord. […] The symptoms you or a loved one might experience if you have medulloblastoma include: […] Headaches, especially in the morning or after lying down: One of the most common symptoms is headaches, which are often worse in the morning or after lying down due to increased pressure in the brain. […] Nausea and vomiting: This symptom will often happen alongside headaches because of the increased pressure from the tumor. […] Balance and coordination problems: Because the cerebellum is responsible for balance and coordination, people with medulloblastomas can experience stumbling, trouble walking, or difficulty with fine motor tasks like writing. […] Vision problems: Blurring or double vision can happen when the tumor creates pressure on the nerves that control eye movement.

• #29 Medulloblastoma – Pediatrics – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pediatrics/pediatric-cancers/medulloblastoma

  Patients present most commonly with symptoms associated with increased intracranial pressure and cerebellar dysfunction, which may include vomiting, headache, nausea, visual changes (eg, double vision), and unsteady walking or clumsiness. […] Prognosis depends on age, stage, histology, cytogenetics, and molecular parameters of the tumor. […] Age 3 years: Likelihood of 5-year disease-free survival is 60 to 70% if the tumor is high risk, and 80% if the tumor is average risk. […] Age 3 years: Prognosis is more problematic, in part because up to 40% of children have disseminated disease at diagnosis and radiation therapy is typically avoided/delayed in this age group. Children who survive are at risk of severe long-term neurocognitive deficits (eg, in memory, verbal learning, and executive function). […] Molecular group WNT-activated has the best prognosis with 90 to 100% overall survival.

• #30 Medulloblastoma (Embryonal Neuroepithelial Tumor) – UC Health

  https://www.uchealth.com/en/conditions/medulloblastoma

  Symptoms of medulloblastoma may start slowly and get worse as the tumor grows. Headaches are common. Sometimes a brain tumor may block the normal flow of cerebral spinal fluid (CSF), leading to increased intracranial pressure. This may cause headache, nausea, vomiting, and dizziness. Because the tumor is often in the cerebellum, it may affect balance and coordination early on. […] Some of the general symptoms of medulloblastoma include: Balance problems or clumsiness. Changes in thinking ability. Dizziness. Double vision or other eye problems. Tiredness and lack of energy (fatigue). Headaches. Nausea and vomiting. Hearing loss. Irritability and changed behavior. […] These are fairly fast-growing tumors. The outlook for tumors that have spread tends to be worse than for tumors that stay in one place.

• #31 Medulloblastoma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 9Group 49

  https://www.barrowneuro.org/condition/medulloblastoma/

  Fatigue and drowsiness: Increased pressure from tumor growth can lead to general fatigue, drowsiness, or lethargy. […] Behavioral changes: Personality or behavioral changes can manifest as new or unusual emotional states, like changes in judgment, aggressiveness, irritability, or loss of initiative. This is especially noteworthy in children. […] Hydrocephalus: When a tumor blocks the flow of cerebrospinal fluid (CSF) and leads to a buildup of fluid in the brain, hydrocephalus can occur. This condition causes severe headaches, nausea and vomiting, changes in behavior or consciousness, and an increase in head size in infants. […] Back pain or difficulty walking: When a medulloblastoma spreads to the spinal cord, it can result in back pain, leg weakness, or even loss of bladder and bowel control.

• #32 Embryonal tumour with multilayered rosettes – Wikipedia

  https://en.wikipedia.org/wiki/Embryonal_tumour_with_multilayered_rosettes

  Embryonal tumor with multilayered rosettes (ETMR) is an embryonal central nervous system tumor. Symptoms depend on the location of the tumor and, thus, may vary, but they may include raised intracranial pressure, paresis, seizures, visual impairments, ataxia, and torticollis. […] Despite aggressive treatment, the prognosis is poor with 5-year overall survival rates less than 30%. Many patients show quick progression of disease, which is often refractory to treatment.

• #33 Embryonal tumor with multilayered rosettes: Overview of diagnosis and therapy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10506690/

  Embryonal tumors with multilayered rosettes (ETMR) are rare but aggressive cancers, commonly occurring in children under 3 years of age. […] The presenting symptoms of ETMR vary and depend on tumor size and location, but the most common clinical sign is raised ICP, […] ETMRs typically present as large, well-defined masses with diffusion restriction on MRI. […] Histologically, characteristic ETMR features include multilayered and pseudo-stratified rosette structures and large areas of neuropil, containing a mixture of dendrites, glial cells, and unmyelinated axons. […] To date, there remains no standard treatment for ETMR and a paucity of prospective clinical data on which to base clinical decision-making. […] Current chemotherapy strategies are based on protocols for young children with CNS primitive neuroectodermal tumor (CNS-PNET), with different intensive combinations used.

• #34 SciELO Brazil – Embryonal tumor with multilayered rosettes in a teenager Embryonal tumor with multilayered rosettes in a teenager

  https://www.scielo.br/j/acrep/a/SpNtCRLvCv5H5cCvHwWx6YQ/

  Embryonal tumors usually affect children less than 4 years old and may occur in any part of the brain, although they are typically seen in the supratentorial region. Patients usually present with signs and symptoms of raised intracranial pressure and/or neurologic deficits. On magnetic resonance imaging (MRI), they show cystic components and intratumoral hemorrhage. […] The behavior of this WHO grade 4 tumor is largely aggressive and the prognosis is dismal. […] Presenting symptoms are similar to other malignant brain tumors that occur at a very young age, and are based on the initial location, the size of tumor and secondary obstruction of cerebrospinal fluid circulation with hydrocephalus. Apart from symptoms of raised intracranial pressure, other symptoms such as paresis, seizures, visual impairment, ataxia and torticollis may occur.

• #35

  https://www.scitechnol.com/peer-review/pediatric-embryonal-tumors-intrue-rosettes-etmrs-presentingas-a-low-grade-glioma-anunusual-case-report-M0ZG.php?article_id=11640

  Pediatric Embryonal Tumors in Multilayered Rosettes (ETMR) are rare aggressive tumors with poor survival statistics, defined by the 2016 WHO classification of brain tumors. […] This combined with a clinical picture of raised intracranial pressure symptoms, seizures and rapidly progressive new onset neurological deficits make the diagnosis fairly obvious. […] The most common clinical manifestations are symptoms and signs of increased intracranial pressure and focal neurological signs. […] The radiological features are similar to other brain tumors. […] The integrated diagnosis should be based on histology (CNS embryonal tumor with multi-layered rosettes), immunoreactivity (synaptophysin, and the specific biomarker LIN28A), and genetics (amplification of C19MC locus at 19q13.42 by FISH wherever possible) to reliably diagnose this novel aggressive brain tumor.

• #36 Embryonal Tumors Causes and Symptoms – Klarity Health Library

  https://my.klarity.health/embryonal-tumors-causes-and-symptoms/

  As the tumor spreads to the spinal cord, it can cause: Backaches, Problems with walking, Bladder and bowel issues. […] Common symptoms associated with AT/RT include: Frequent headaches, Nausea and vomiting, Fatigue, Coordination issues. […] This type of tumor is usually found in the cerebral hemisphere of the brain. ETMR is a malignant type of tumor with low survival rates of only around a year. Some of the symptoms associated with this type of tumor include headaches, seizures and facial paralysis. […] The symptoms include: Fatigue, tiredness, Loss of appetite, Bone pain, Weakness. […] Symptoms of these tumor types are often shared with each other and with other diseases, making it difficult to diagnose. Symptoms also depend on where in the central nervous system the tumor begins to grow. As many of these tumors progress very quickly and are quite debilitating, early detection is vital to ensure best prognosis and survival.

• #37 Aggressive Infantile Embryonal Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3674573/

  Embryonal tumors are the most common brain tumors in infants less than 36 months of age. […] All of the infantile embryonal tumors are similarly aggressive and have a proclivity to disseminate throughout the central nervous system early in the course of illness. […] Outcomes remain similarly poor among all the infantile embryonal tumor types and, therefore, identification of specific molecular targets that have prognostic and therapeutic implications is crucial. […] Children classically present with the signs and symptoms of obstruction of cerebrospinal fluid flow and cerebellar dysfunction. Infants with medulloblastoma may present less characteristically and have intermittent vomiting, macrocephaly, and nonspecific signs of ventricular dilatation, including the sun-setting sign where there is an inability to elevate the eyes.

• #38 Aggressive Infantile Embryonal Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3674573/

  Staging studies are crucial in the evaluation of most embryonal tumors, including medulloblastoma. […] The overall outcome for children with supratentorial primitive neuroectodermal tumors is relatively poor. […] The management of atypical teratoid/rhabdoid tumors, as is the case with other embryonal tumors, begins with staging. The utility of surgery, radiotherapy, and chemotherapy for children, especially infants with atypical teratoid/rhabdoid tumors, is under active study.

• #39

  https://journals.lww.com/ijpm/fulltext/2022/65001/embryonal_tumors_in_the_who_cns5_classification__a.11.aspx

  Embryonal tumors are a heterogenous group of neoplasms mostly defined by recurrent genetic driver events. […] The combination of histopathological and molecular features reflects the complexity of all these tumors and gives critical information in terms of prognosis and therapy. […] The most important change in CNS5 is the identification of three molecular sub-groups defined by DNA methylation and/or gene expression profiling. […] AT/RT-SHH tumors (~44%) exhibit an overexpression of proteins involved in the pathways of SHH and Notch signaling. […] The median age of patients is 20 months and in 67% of cases, they arise in the supratentorial compartment. […] AT/RT-TYR tumors (~34%) are characterized by an upregulation of proteins involved in the melanosomal pathway (tyrosinase), the bone morphogenetic protein (BMP) pathway, and development-related transcription factors, including OTX2.

• #40 Embryonal Carcinoma: Symptoms & Prognosis

  https://my.clevelandclinic.org/health/diseases/embryonal-carcinoma

  Symptoms of embryonal carcinoma include: A swollen testicle. A (painful or painless) mass or lump in your testicle. Heaviness or discomfort in your scrotum. […] Other symptoms may be signs that the cancer has spread beyond your testicle. These include: Low back pain. Flank pain. Shortness of breath (dyspnea). Cough or coughing up blood (hemoptysis). […] Embryonal carcinomas form when germ cells multiply out of control. Eventually, the cells form a mass, or tumor. These tumors tend to grow fast and spread beyond your testicle. […] As part of your diagnosis, your provider will determine your cancer stage, or how advanced it is. Cancer stage is the best predictor of your prognosis. Early-stage embryonal carcinoma is often curable. But it spreads so fast that up to 40% of cancers have already metastasized (spread to distant parts of your body) by the time providers diagnose them.

• #41 Embryonal carcinoma – Wikipedia

  https://en.wikipedia.org/wiki/Embryonal_carcinoma

  The presenting features may be a palpable testicular mass or asymmetric testicular enlargement in some cases. The tumour may present as signs and symptoms relating to the presence of widespread metastases, without any palpable lump in the testis. The clinical features associated with metastasising embryonal carcinoma may include low back pain, dyspnoea, cough, haemoptysis, haematemesis and neurologic abnormalities. […] In the ovary, embryonal carcinoma is quite rare, amounting to approximately three percent of ovarian germ cell tumours. The median age at diagnosis is 15 years. Symptoms and signs are varied, and may include sexual precocity and abnormal (increased, reduced or absent) uterine bleeding. […] In the testis pure embryonal carcinoma is also uncommon, and accounts for approximately ten percent of testicular germ cell tumours. However, it is present as a component of almost ninety percent of mixed nonseminomatous germ cell tumours. The average age at diagnosis is 31 years, and typically presents as a testicular lump which may be painful. One-fifth to two-thirds of patients with tumours composed predominantly of embryonal carcinoma have metastases at diagnosis.

• #42 Embryonal Carcinoma: Symptoms & Prognosis

  https://my.clevelandclinic.org/health/diseases/embryonal-carcinoma

  Symptoms of embryonal carcinoma include: A swollen testicle. A (painful or painless) mass or lump in your testicle. Heaviness or discomfort in your scrotum. […] Other symptoms may be signs that the cancer has spread beyond your testicle. These include: Low back pain. Flank pain. Shortness of breath (dyspnea). Cough or coughing up blood (hemoptysis). […] Embryonal carcinomas form when germ cells multiply out of control. Eventually, the cells form a mass, or tumor. These tumors tend to grow fast and spread beyond your testicle. […] As part of your diagnosis, your provider will determine your cancer stage, or how advanced it is. Cancer stage is the best predictor of your prognosis. Early-stage embryonal carcinoma is often curable. But it spreads so fast that up to 40% of cancers have already metastasized (spread to distant parts of your body) by the time providers diagnose them.

• #43 Embryonal carcinoma – Wikipedia

  https://en.wikipedia.org/wiki/Embryonal_carcinoma

  The presenting features may be a palpable testicular mass or asymmetric testicular enlargement in some cases. The tumour may present as signs and symptoms relating to the presence of widespread metastases, without any palpable lump in the testis. The clinical features associated with metastasising embryonal carcinoma may include low back pain, dyspnoea, cough, haemoptysis, haematemesis and neurologic abnormalities. […] In the ovary, embryonal carcinoma is quite rare, amounting to approximately three percent of ovarian germ cell tumours. The median age at diagnosis is 15 years. Symptoms and signs are varied, and may include sexual precocity and abnormal (increased, reduced or absent) uterine bleeding. […] In the testis pure embryonal carcinoma is also uncommon, and accounts for approximately ten percent of testicular germ cell tumours. However, it is present as a component of almost ninety percent of mixed nonseminomatous germ cell tumours. The average age at diagnosis is 31 years, and typically presents as a testicular lump which may be painful. One-fifth to two-thirds of patients with tumours composed predominantly of embryonal carcinoma have metastases at diagnosis.

• #44 Aggressive Infantile Embryonal Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3674573/

  Embryonal tumors are the most common brain tumors in infants less than 36 months of age. […] All of the infantile embryonal tumors are similarly aggressive and have a proclivity to disseminate throughout the central nervous system early in the course of illness. […] Outcomes remain similarly poor among all the infantile embryonal tumor types and, therefore, identification of specific molecular targets that have prognostic and therapeutic implications is crucial. […] Children classically present with the signs and symptoms of obstruction of cerebrospinal fluid flow and cerebellar dysfunction. Infants with medulloblastoma may present less characteristically and have intermittent vomiting, macrocephaly, and nonspecific signs of ventricular dilatation, including the sun-setting sign where there is an inability to elevate the eyes.

• #45 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. […] The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

• #46 Primitive Neuroectodermal Tumor – MD Searchlight

  https://mdsearchlight.com/cancer/primitive-neuroectodermal-tumor/

  Children with these tumors may show different symptoms. For instance, younger children often show irritability, vomiting, and visual issues, while those older than three years usually exhibit headaches, vomiting, and balance problems. […] These aggressive tumors are typically detected within a short time, about 20 days, from the first observable symptom. Tumors in the lower part of the brain, high-grade tumors, and those in younger patients tend to be diagnosed quickest.

• #47 Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment – Health Professional Information [NCI] – Health Information Library | PeaceHealth

  https://www.peacehealth.org/medical-topics/id/ncicdr0000548358

  The optimal treatment of childhood nonmedulloblastoma embryonal tumors remains unclear and under study. […] Nonmedulloblastoma embryonal tumors may occur anywhere in the CNS, and presentation is variable. Usually there is significant neurological dysfunction associated with lethargy and vomiting. […] For nonmedulloblastoma embryonal tumors, presentation is also relatively rapid and depends on the location of the tumor in the nervous system. Embryonal tumors tend to grow fast and are usually diagnosed within 3 months of initial onset of symptoms. […] In one study of 58 children with pineoblastoma, a subclassification schema was presented, and it separated patients into four subgroups. […] Pineoblastoma often results in hydrocephalus due to blockage of cerebrospinal fluid at the third ventricular level and other symptoms related to pressure on the back of the brain stem in the tectal region. Symptoms may include a constellation of abnormalities in eye movements (Parinaud syndrome), manifested by pupils that react poorly to light but better to accommodation, loss of upgaze, retraction or convergence nystagmus, and lid retraction.

• #48 Brain and Spinal Cord Tumors – Liv Hospital

  https://www.livhospital.com/brain-and-spinal-cord-tumors

  These tumors develop from embryonal cells in the central nervous system during fetal development. After birth, most embryonal tumors in children become malignant. These tumors tend to grow rapidly and may spread to other parts of the brain and spinal cord. […] Symptoms of a brain or spinal cord tumor depend on the tumor’s size, type, and location. A tumor causing pressure on a nerve or damaging a part of the brain can lead to symptoms. Additionally, a tumor blocking the flow of cerebrospinal fluid can result in hydrocephalus or brain swelling. […] Common symptoms of brain and spinal cord tumors include: Balance problems, Back pain or numbness, Changes in mood, personality, or concentration, Changes in speech, vision, or hearing, Headaches (usually worse in the morning), Memory problems, Nausea and vomiting, Numbness or tingling in the arms or legs, Seizures, Scoliosis (curvature of the spine).

• #49 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Diagnosis is usually made by either magnetic resonance imaging (MRI) or computed tomography (CT) scan. MRI is preferable because the anatomical relationship between the tumor and surrounding brain and tumor dissemination is better visualized with this method. […] Given the tendency of these tumors to disseminate throughout the CNS early in the course of illness, imaging evaluation of the neuraxis by MRI of the entire brain and spine is indicated. […] Patients with disseminated CNS disease at diagnosis are at highest risk of disease relapse. […] Ten percent to 40% of patients with medulloblastoma have CNS dissemination at diagnosis. Infants have the highest incidence and adolescents and adults have the lowest incidence of CNS dissemination. […] Nonmedulloblastoma embryonal tumors and pineoblastomas may also be disseminated at the time of diagnosis, although the incidence may be somewhat less than for medulloblastomas, with dissemination at diagnosis in approximately 10% to 20% of patients.

• #50 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Diagnosis is usually made by either magnetic resonance imaging (MRI) or computed tomography (CT) scan. MRI is preferable because the anatomical relationship between the tumor and surrounding brain and tumor dissemination is better visualized with this method. […] Given the tendency of these tumors to disseminate throughout the CNS early in the course of illness, imaging evaluation of the neuraxis by MRI of the entire brain and spine is indicated. […] Patients with disseminated CNS disease at diagnosis are at highest risk of disease relapse. […] Ten percent to 40% of patients with medulloblastoma have CNS dissemination at diagnosis. Infants have the highest incidence and adolescents and adults have the lowest incidence of CNS dissemination. […] Nonmedulloblastoma embryonal tumors and pineoblastomas may also be disseminated at the time of diagnosis, although the incidence may be somewhat less than for medulloblastomas, with dissemination at diagnosis in approximately 10% to 20% of patients.

• #51 Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment – Health Professional Information [NCI] – Health Information Library | PeaceHealth

  https://www.peacehealth.org/medical-topics/id/ncicdr0000548358

  Given the tendency of these tumors to disseminate throughout the CNS early in the course of illness, imaging evaluation of the neuraxis by MRI of the entire brain and spine is indicated. […] Patients with disseminated CNS disease at diagnosis are at highest risk of disease relapse. […] Ten percent to 40% of patients with medulloblastoma have CNS dissemination at diagnosis, with infants having the highest incidence and adolescents and adults having the lowest incidence. […] Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery.

• #52 Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion | Acta Neuropathologica Communications | Full Text

  https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01746-7

  Central nervous system (CNS) embryonal tumors are a heterogeneous group of high-grade malignancies, and the increasing clinical use of methylation profiling and next-generation sequencing has led to the identification of molecularly distinct subtypes. […] We find that patients are young (4 years or younger), with large tumors at variable locations, and frequently with evidence of leptomeningeal/cerebrospinal fluid (CSF) dissemination. […] Two patients with clinical follow up available had tumors with excellent response to chemotherapy. Two of our patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy at 16 and 33 months. One patient relapsed, and the last of our four patients died of disease one month after diagnosis. […] With respect to patient follow-up, cases #1 (15-month-old female) and #2 (3-year-old male) were both alive without evidence of recurrence or progression at with near total resection followed by chemotherapy.

• #53 Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment – Health Professional Information [NCI] – Health Information Library | PeaceHealth

  https://www.peacehealth.org/medical-topics/id/ncicdr0000548358

  In older studies, the extent of resection for medulloblastomas was found to be related to survival. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] Patients with nonmedulloblastoma embryonal tumors and pineoblastomas may also be disseminated at the time of diagnosis, although the incidence of dissemination may be somewhat less than that of medulloblastomas, with dissemination at diagnosis being documented in approximately 10% to 20% of patients. […] Patients with nonmedulloblastoma embryonal tumors and pineoblastomas who have disseminated disease at the time of diagnosis have a poor OS, with reported survival rates at 5 years ranging from 10% to 30%.

• #54 Medulloblastoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1181219-overview

  Symptoms are often progressive over weeks to months, and it is not uncommon for patients to have an extended symptomatic period prior to initial diagnosis. […] Symptoms usually differ by anatomic location of the tumor, presence of disseminated disease, and by the presence of hydrocephalus. […] Medulloblastoma is a very aggressive tumor. Even after a good response to surgery and radiation, recurrence is common; most recurrences occur within 2 years after treatment. […] The most common location of recurrence is at the primary tumor site in the posterior fossa. […] Systemic metastases, in the absence of a CSF shunting system, are also a recognized problem in 10-20% of patients. Bone is the most common site of systemic metastasis; regional lymph node sites follow. […] The 5-year progression-free survival rate in that group is 70-80% for patients at low risk and 60-70% for patients at high risk.

• #55 Medulloblastoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1181219-overview

  Symptoms are often progressive over weeks to months, and it is not uncommon for patients to have an extended symptomatic period prior to initial diagnosis. […] Symptoms usually differ by anatomic location of the tumor, presence of disseminated disease, and by the presence of hydrocephalus. […] Medulloblastoma is a very aggressive tumor. Even after a good response to surgery and radiation, recurrence is common; most recurrences occur within 2 years after treatment. […] The most common location of recurrence is at the primary tumor site in the posterior fossa. […] Systemic metastases, in the absence of a CSF shunting system, are also a recognized problem in 10-20% of patients. Bone is the most common site of systemic metastasis; regional lymph node sites follow. […] The 5-year progression-free survival rate in that group is 70-80% for patients at low risk and 60-70% for patients at high risk.

• #56 Childhood Medulloblastoma & Other CNS Embryonal Tumors Treatment – NCI

  https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq

  The risk for medulloblastoma is increased in people who have any of the following inherited diseases: Turcot syndrome, Rubinstein-Taybi syndrome, Nevoid basal cell carcinoma (Gorlin) syndrome, Li-Fraumeni syndrome, Fanconi anemia. […] Certain factors affect prognosis (chance of recovery) and treatment options. […] The prognosis and treatment options depend on: the type of tumor and where it is in the brain; whether the cancer has spread within the brain and spinal cord when the tumor is found; the age of the child when the tumor is found; how much of the tumor remains after surgery; whether there are certain changes in the chromosomes, genes, or brain cells; whether the tumor has just been diagnosed or has recurred (come back). […] Childhood medulloblastoma and other types of CNS embryonal tumors most often recur (come back) within 3 years after treatment but may come back many years later. Recurrent childhood medulloblastoma and other CNS embryonal tumors may come back in the same place as the original tumor and/or in a different place in the brain or spinal cord.

• #57 Central Nervous System Embryonal Tumors Treatment | Montefiore Einstein Comprehensive Cancer Center | Patient Care | Montefiore Einstein

  https://montefioreeinstein.org/cancer/types/childhood/central-nervous-system-embryonal-tumors-treatment

  Infants and young children with these tumors may be irritable or grow slowly. Also they may not eat well or meet developmental milestones such as sitting, walking, and talking in sentences. These tumors may also cause an increase in the size of an infant’s head. […] These symptoms may be caused by problems other than medulloblastoma, other CNS embryonal tumors, or pineoblastoma. The only way to know is to see your child’s doctor. […] Most medulloblastomas, other CNS embryonal tumors, and pineoblastomas in children are malignant. These tumors tend to spread through the cerebrospinal fluid to other parts of the brain and spinal cord. […] Childhood medulloblastoma and other types of CNS embryonal tumors most often recur (come back) within 3 years after treatment but may come back many years later. Recurrent childhood medulloblastoma and other CNS embryonal tumors may come back in the same place as the original tumor and/or in a different place in the brain or spinal cord.

• #58 Embryonal Carcinoma: Symptoms & Prognosis

  https://my.clevelandclinic.org/health/diseases/embryonal-carcinoma

  The biggest indicator of your prognosis (outlook) is the tumor stage. According to a recent study tracking embryonal carcinoma survival rates, over 98% of people treated for Stage I cancer were alive five years later. Around 80% with Stage III embryonal carcinoma were alive five years later. […] Even if you respond well to treatment, your healthcare provider will continue to monitor you in case the cancer returns. With embryonal carcinoma, there’s a 20% chance of recurrence if the cancer’s only in your testicle. The likelihood of recurrence increases to over 50% if the cancer is in your scrotum or lymph nodes.

• #59 Medulloblastoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1181219-overview

  Symptoms are often progressive over weeks to months, and it is not uncommon for patients to have an extended symptomatic period prior to initial diagnosis. […] Symptoms usually differ by anatomic location of the tumor, presence of disseminated disease, and by the presence of hydrocephalus. […] Medulloblastoma is a very aggressive tumor. Even after a good response to surgery and radiation, recurrence is common; most recurrences occur within 2 years after treatment. […] The most common location of recurrence is at the primary tumor site in the posterior fossa. […] Systemic metastases, in the absence of a CSF shunting system, are also a recognized problem in 10-20% of patients. Bone is the most common site of systemic metastasis; regional lymph node sites follow. […] The 5-year progression-free survival rate in that group is 70-80% for patients at low risk and 60-70% for patients at high risk.

• #60

  https://braintumourresearch.org/pages/types-of-brain-tumours-embryonal-tumours?srsltid=AfmBOopgWZYlC6zgqhNs-WM9neO1MlS4Yc5_hIdBfbEiKQOQPNfbxMEq

  Embryonal tumours represent 20% to 25% of primary paediatric central nervous system (CNS) tumours, with medulloblastoma accounting for the majority of these tumours. […] The prognosis for each type of embryonal tumour is included in the relevant section above, but overall survival rates for embryonal tumours (not including medulloblastoma) are generally poor, ranging from less than 5% to 50% of patients surviving more than 5 years from diagnosis. […] Signs and symptoms of embryonal tumours depend upon where the tumour has developed. Common symptoms include headaches, seizures, muscular weakness or partial paralysis of facial muscles, and muscular weakness or partial paralysis on one side of the body.

• #61 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. […] The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

• #62 Childhood Medulloblastoma & Other CNS Embryonal Tumors Treatment – NCI

  https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq

  The risk for medulloblastoma is increased in people who have any of the following inherited diseases: Turcot syndrome, Rubinstein-Taybi syndrome, Nevoid basal cell carcinoma (Gorlin) syndrome, Li-Fraumeni syndrome, Fanconi anemia. […] Certain factors affect prognosis (chance of recovery) and treatment options. […] The prognosis and treatment options depend on: the type of tumor and where it is in the brain; whether the cancer has spread within the brain and spinal cord when the tumor is found; the age of the child when the tumor is found; how much of the tumor remains after surgery; whether there are certain changes in the chromosomes, genes, or brain cells; whether the tumor has just been diagnosed or has recurred (come back). […] Childhood medulloblastoma and other types of CNS embryonal tumors most often recur (come back) within 3 years after treatment but may come back many years later. Recurrent childhood medulloblastoma and other CNS embryonal tumors may come back in the same place as the original tumor and/or in a different place in the brain or spinal cord.

• #63 Medulloblastoma – Pediatrics – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pediatrics/pediatric-cancers/medulloblastoma

  Patients present most commonly with symptoms associated with increased intracranial pressure and cerebellar dysfunction, which may include vomiting, headache, nausea, visual changes (eg, double vision), and unsteady walking or clumsiness. […] Prognosis depends on age, stage, histology, cytogenetics, and molecular parameters of the tumor. […] Age 3 years: Likelihood of 5-year disease-free survival is 60 to 70% if the tumor is high risk, and 80% if the tumor is average risk. […] Age 3 years: Prognosis is more problematic, in part because up to 40% of children have disseminated disease at diagnosis and radiation therapy is typically avoided/delayed in this age group. Children who survive are at risk of severe long-term neurocognitive deficits (eg, in memory, verbal learning, and executive function). […] Molecular group WNT-activated has the best prognosis with 90 to 100% overall survival.

• #64 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. […] The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

• #65 Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience

  https://www.mdpi.com/2227-9067/9/10/1560

  The location of tumor incidence and the absence of distant metastases during initial treatment are also closely related to the prognosis of the disease. […] It is still controversial whether ETMR patients should receive adjuvant chemotherapy after surgery. […] The previous studies indicated that postoperative adjuvant radiotherapy can improve the prognosis and prolong the overall survival rate for ETMR patients. […] In conclusion, we formulated a treatment strategy for ETMRs, varied according to the tumor stage. Maximum excision is the mainstream treatment, but patients could also benefit from adjuvant chemotherapy.

• #66 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. […] The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

• #67 Medulloblastoma – Pediatrics – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pediatrics/pediatric-cancers/medulloblastoma

  Patients present most commonly with symptoms associated with increased intracranial pressure and cerebellar dysfunction, which may include vomiting, headache, nausea, visual changes (eg, double vision), and unsteady walking or clumsiness. […] Prognosis depends on age, stage, histology, cytogenetics, and molecular parameters of the tumor. […] Age 3 years: Likelihood of 5-year disease-free survival is 60 to 70% if the tumor is high risk, and 80% if the tumor is average risk. […] Age 3 years: Prognosis is more problematic, in part because up to 40% of children have disseminated disease at diagnosis and radiation therapy is typically avoided/delayed in this age group. Children who survive are at risk of severe long-term neurocognitive deficits (eg, in memory, verbal learning, and executive function). […] Molecular group WNT-activated has the best prognosis with 90 to 100% overall survival.

• #68 Molecular mechanism and therapeutic strategies for embryonal tumors with multilayered rosettes in children (Review)

  https://www.spandidos-publications.com/10.3892/mco.2025.2825?text=fulltext

  Embryonal tumors with multilayered rosettes (ETMR) are relatively rare but highly aggressive intracranial tumors that mainly occur in children under four years of age. […] The five-year overall survival (OS) rate of patients with ETMR remains 30%. […] For patients receiving chemotherapy, the median OS time was 7.4 months, whereas that of those who did not receive it was 1.2 months. […] For patients with non-brainstem tumor location, the five-year progression-free survival (PFS) and OS were 35 and 47%, respectively, after treatment with intensified chemotherapy. […] The treatment of patients with ETMR has only slightly improved, and the five-year OS rate remains 30%. […] Despite the availability of various therapeutic strategies, ETMR remains a highly lethal disease.

• #69 Embryonal Carcinoma: Symptoms & Prognosis

  https://my.clevelandclinic.org/health/diseases/embryonal-carcinoma

  The biggest indicator of your prognosis (outlook) is the tumor stage. According to a recent study tracking embryonal carcinoma survival rates, over 98% of people treated for Stage I cancer were alive five years later. Around 80% with Stage III embryonal carcinoma were alive five years later. […] Even if you respond well to treatment, your healthcare provider will continue to monitor you in case the cancer returns. With embryonal carcinoma, there’s a 20% chance of recurrence if the cancer’s only in your testicle. The likelihood of recurrence increases to over 50% if the cancer is in your scrotum or lymph nodes.

• #70

  https://braintumourresearch.org/pages/types-of-brain-tumours-embryonal-tumours?srsltid=AfmBOopgWZYlC6zgqhNs-WM9neO1MlS4Yc5_hIdBfbEiKQOQPNfbxMEq

  Embryonal tumours represent 20% to 25% of primary paediatric central nervous system (CNS) tumours, with medulloblastoma accounting for the majority of these tumours. […] The prognosis for each type of embryonal tumour is included in the relevant section above, but overall survival rates for embryonal tumours (not including medulloblastoma) are generally poor, ranging from less than 5% to 50% of patients surviving more than 5 years from diagnosis. […] Signs and symptoms of embryonal tumours depend upon where the tumour has developed. Common symptoms include headaches, seizures, muscular weakness or partial paralysis of facial muscles, and muscular weakness or partial paralysis on one side of the body.

• #71 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  Age younger than 3 years at diagnosis portends an unfavorable outcome for those with medulloblastoma and, possibly, other embryonal tumors. […] As a predictor of outcome, postoperative MRI measurement of the amount of residual disease after definitive surgery has been supplanted by extent of resection after surgery. […] The presence of brain stem involvement in children with medulloblastoma was found to be a prognostic factor. […] Prognosis is poor for patients with medulloepithelioma and ETMR, with 5-year survival rates ranging between 0% and 30%. […] The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. […] The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

• #72

  https://link.springer.com/article/10.1007/s11060-024-04667-6

  Central nervous system (CNS) embryonal tumors are a diverse group of malignant tumors typically affecting pediatric patients that recently have been better defined, and this paper describes evolution of a unique type of embryonal tumor at relapse. […] Atypical teratoid rhabdoid tumors (ATRT) are a type of CNS-ET that more commonly occurs in infants and carry a poor prognosis. […] Patients at the age where craniospinal radiation is thought to carry reasonable neurocognitive outcomes can be treated with craniospinal radiation followed by maintenance chemotherapy. […] The fact that the disease for these two patients were assigned a different methylation class upon development of the SMARCB1 alterations at recurrence is notable. Change of DNA methylation class between primary and recurrent tumor is very unusual for brain tumors and this may represent one of the few exceptions and needs to be verified in larger cohort of patients. Our patients progressed rapidly once the tumor primarily had INI-1 deficiency, and the second patient which showed some INI-1 loss at diagnosis by IHC had a more rapid clinical progression, and this focal losses of nuclear INI-1 expression in an ET may be a clue to the diagnosis and nature of these neoplasms.

• #73 Embryonal tumor with multilayered rosettes: Overview of diagnosis and therapy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10506690/

  Due to the deleterious effects of radiation to the developing brain, radiotherapy is not always delivered to ETMR patients. […] Given that ETMR commonly arises during early childhood, the potential benefit of radiotherapy needs to be balanced against the high risk for impairment of neurocognitive function. […] Unfortunately, despite intensive surgical, chemotherapy, and radiotherapy treatments, 5-year OS remains poor, highlighting the need for novel therapeutic strategies.

• #74 Aggressive Infantile Embryonal Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3674573/

  Staging studies are crucial in the evaluation of most embryonal tumors, including medulloblastoma. […] The overall outcome for children with supratentorial primitive neuroectodermal tumors is relatively poor. […] The management of atypical teratoid/rhabdoid tumors, as is the case with other embryonal tumors, begins with staging. The utility of surgery, radiotherapy, and chemotherapy for children, especially infants with atypical teratoid/rhabdoid tumors, is under active study.

• #75 Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics

  https://www.mdpi.com/2306-5354/5/4/78

  The role of high-dose chemotherapy (HDC) followed by stem-cell rescue in studies by the Head Start and the Canadian Brain Tumor Consortia showed improved outcomes with intensive chemotherapy regimens, though toxicity was not inconsequential. […] The current COG ACNS0333 trial incorporates a combination of chemotherapy and radiation therapy, along with autologous stem-cell rescue in treating young patients with ATRT. […] The uniformity of C19MC amplification in these tumors led to the restructuring of ETMR classification. […] These biological revelations provide the initial clues to profile treatment using a targeted therapeutic approach with conventional chemotherapeutic agents.

• #76 Childhood Medulloblastoma and Other CNS Embryonal Tumors (PDQ®) – NCI

  https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq

  In patients with other forms of embryonal tumors, the extent of resection has not been definitively shown to impact survival. […] For patients with recurrent medulloblastoma, treatment approaches may include surgery, radiation therapy, chemotherapy, high-dose chemotherapy with stem cell rescue, and molecularly targeted therapy. […] Recurrent CNS embryonal tumors can respond to chemotherapeutic agents used singularly or in combination, including cyclophosphamide, cisplatin, carboplatin, lomustine, etoposide, topotecan, temozolomide, the combination of irinotecan and temozolomide with or without bevacizumab, and antiangiogenic metronomic therapy.

• #77

  https://link.springer.com/article/10.1007/s11060-024-04667-6

  These patients could potentially benefit from strategies that have resulted in improvement in outcomes in ATRT including high dose chemotherapy with autologous stem cell rescue and early focal radiation, incorporation of intrathecal chemotherapy at diagnosis, high dose early craniospinal radiation in older patients, and newer therapies that have shown promise for INI-1 deficient tumors.

• #78 Embryonal Brain Tumor Treatment in India: A Comprehensive Guide For Parents – GoMedii Blog

  https://gomedii.com/blogs/english/health-a2z/embryonal-brain-tumor-treatment-in-india-a-comprehensive-guide-for-parents/

  Embryonal brain tumors are a rare yet concerning issue in kids around the world. Dealing with it can be tough for kids and parents. However, having knowledge about early symptoms, disease types, and available treatment options can help in early intervention. India with its exceptional medical infrastructure, skilled professionals, and affordable prices can help your child recover from this deadly disease effectively.

• #79 Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion | Acta Neuropathologica Communications | Full Text

  https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01746-7

  Our sample size is small, but initial clinical investigation showed that these were clinically aggressive, and the evolution of patient #5, who died of disease progression shortly after surgery, is in line with these features. Nevertheless, two patients who underwent stereotactic biopsies showed tumor reduction with chemotherapy, permitting subsequent gross total resection, though one of these relapsed. Two patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy 16 and 33 months after initial diagnosis, one of them already one year off-therapy, suggesting that at least some of these tumors may benefit from chemotherapy.

• #80 Molecular mechanism and therapeutic strategies for embryonal tumors with multilayered rosettes in children (Review)

  https://www.spandidos-publications.com/10.3892/mco.2025.2825?text=fulltext

  Embryonal tumors with multilayered rosettes (ETMR) are relatively rare but highly aggressive intracranial tumors that mainly occur in children under four years of age. […] The five-year overall survival (OS) rate of patients with ETMR remains 30%. […] For patients receiving chemotherapy, the median OS time was 7.4 months, whereas that of those who did not receive it was 1.2 months. […] For patients with non-brainstem tumor location, the five-year progression-free survival (PFS) and OS were 35 and 47%, respectively, after treatment with intensified chemotherapy. […] The treatment of patients with ETMR has only slightly improved, and the five-year OS rate remains 30%. […] Despite the availability of various therapeutic strategies, ETMR remains a highly lethal disease.

Zobacz więcej